CLINUVEL Kommuniqué III
Sehr geehrte Aktionärinnen und Aktionäre, liebe Freunde, EINFÜHRUNG Während des Lockdown hatte...
Read More
CLINUVEL Communiqué III
Dear shareholders, friends, INTRODUCTION During the lockdowns our team has had plenty...
Read More
SCIENTIFIC COMMUNIQUÉ X: Photoprotection and the significance of Minimal Erythema Dose (MED) testing
May 2021 ABSTRACT The sun continuously emits radiant energy across the solar...
Read More
CLINUVEL Kommuniqué II
Liebe Aktionäre, Freunde Wir begrüßen viele neue Aktionäre, insbesondere die große Anzahl...
Read More
CLINUVEL Communiqué II
Dear shareholders, friends We welcome many new shareholders, especially the large number...
Read More
SCIENTIFIC COMMUNIQUÉ IX
Beyond Pigment, the Melanocortin 1 Receptor (MC1R) in DNA Repair March 2021...
Read More
Financial Results Half Year Ended 31 December 2020
Operations Update I Webinar CLINUVEL PHARMACEUTICALS LTD CLINUVEL PHARMACEUTICALS LTD will host...
Read More
Kommuniqué I
Liebe Freunde, Aktionäre, Wir sind in ein neues Jahr eingetreten, eines voller...
Read More
CLINUVEL Communiqué I
Dear friends, shareholders, We have entered a new year, one brimmed with...
Read More
CLINUVEL Newsletter VI
Dear shareholders, friends, CLINUVEL’S OUTLOOK The past weeks have seen a flurry...
Read More
SCIENTIFIC COMMUNIQUÉ VIII
DNA Repair Mechanisms December 2020 Introduction DNA is the repository of genetic...
Read More
SCIENTIFIC COMMUNIQUÉ VII
The Cerebral Vasculature System in Disease: Atherosclerosis Introduction The human brain is...
Read More
Chair's Letter To Shareholders
19 November 2020 Dear fellow shareholder, I look back at a year...
Read More
SCIENTIFIC COMMUNIQUÉ VI
Ultraviolet Radiation Damage and Oxidative Stress in Skin Cancer. October 2020 Introduction...
Read More